Epilepsy

Previously approved for use in adults with epilepsy in 2018, the band uses pattern detection to pick up on movement and physiological signatures indicating the occurrence of generalized tonic-clonic seizures.

The professor of pediatrics at Tel Aviv University explained what has been fleshed out by the research and shared his opinion on cannabidiol’s use.

The Clinical Director of the NHGRI spoke about the impact of the NIH program and its future development.

The director of the Jefferson Comprehensive Epilepsy Center and the Jefferson Clinical Neurophysiology Laboratory spoke to the therapy’s success thus far.

The position statement’s author noted that a lack of specificity in laws and inconsistencies in protocols has led to confusion surrounding brain death in several high-profile cases.

The program’s director spoke about its genesis and evolution into a more widespread initiative which has helped improve next-generation genome sequencing.

The head of the Children’s Brain Dynamics Laboratory at Boston Children’s Hospital discussed the HOPE project and its goals moving forward.

The pediatric epileptologist and adjunct professor of pediatrics at the University of Calgary spoke about how drastically things have changed surrounding the patient-physician conversation about SUDEP.

The director of the Jefferson Comprehensive Epilepsy Center and the Jefferson Clinical Neurophysiology Laboratory provided insight about the phase 3 safety trial of cenobamate.

Because the drug candidate has shown a competitive efficacy and safety profile compared with existing drugs in recent partial focal epilepsy studies, a phase 3 study was initiated.

A recent review of treatments for pediatric status epilepticus included a critical assessment of non-medicinals which detailed that the evidence for their use is mostly anecdotal.

Neurology News Network for the week of December 22, 2018.

The Director of the Cleveland Clinic Epilepsy Center spoke about how important it is for clinicians to not select the wrong patients for deep brain stimulation.

The treatment is the first approved novel, oral once-daily extended release formulation of oxcarbazepine for the treatment of partial-onset seizures in patients aged 6 years and older.

The professor and head of the Department of Neurology and Rehabilitation at the University of Illinois at Chicago spoke about how data can better inform epilepsy care.

The epileptologist at the University of Pennsylvania spoke about the multiple options for patients with epilepsy and the need for a better understanding of choosing from the options.

A middle-aged man explains that his seizures occur almost daily, and he suggests that either diazepam or the recently approved cannabis (CBD) medication would help control them.

The director of the epilepsy center at Cleveland Clinic spoke about the process that leads to the selection of candidacy for deep brain stimulation.

The director of the Epilepsy Center at Children's Health spoke about the findings of the clinical screening program, and how depression is often overlooked in patients with epilepsy.

The chief medical officer at SK Life Science discussed what makes cenobamate unique, as well as what current studies have discovered.

The pediatric psychologist at Children’s Medical Center discussed what her team does to assess patients in the clinic when something comes up as a result of a patient’s screening.

The Director of the Epilepsy Division at Mayo Clinic in Phoenix discussed the issue of driving when withdrawing patients off seizure medication either because of treatment, remission or surgical intervention.

The section chief of pediatric neurology at Nationwide Children’s Hospital discussed cannabidiol's potential in the Lennox-Gastaut syndrome space.

The Director of the Stanford Epilepsy Center discussed the work that’s left to be done in the field of epilepsy.

The instructor in neurology at Beth Israel Deaconess Medical Center spoke about what clinicians can do right now to mitigate the risk of SUDEP and the myriad of options for them to utilize.